Bipartisan Bill Seeks to Streamline FDA Biosimilar Approvals, Expand Access to Lower-Cost Biologics
核心洞察
Representatives Langworthy and Schrier introduced bipartisan legislation to streamline FDA biosimilar (搜索) approval pathways by reducing clinical study requirements.
The bill aims to codify that the default expectation for biosimilar (搜索) licensure does not include pharmacodynamic or comparative clinical efficacy studies.
Expanding biosimilar (搜索) competition is intended to lower prescription drug costs and improve patient access to biologic therapies.
Representatives Nicholas A. Langworthy (R-NY) and Kim Schrier (D-WA) have introduced bipartisan legislation aimed at accelerating the approval of biosimilar (搜索) products by the U.S. Food and Drug Administration, a move designed to foster greater competition in the biologics market and reduce prescription drug costs for American patients.
The bill, designated H.R.9661, would amend the Public Health Service Act to codify that the default expectation for licensure of biological products as biosimilar (搜索) does not include clinical studies assessing pharmacodynamics or comparative clinical efficacy. By removing these requirements as standard expectations, the legislation seeks to streamline the regulatory pathway and lower the barriers to market entry for biosimilar developers.
The proposal reflects a growing recognition among policymakers that biosimilars represent a critical mechanism for introducing price competition into the biologics sector, which accounts for a substantial and growing share of U.S. pharmaceutical spending. Biologics, which are complex molecules derived from living organisms, are among the most expensive prescription drugs on the market, and their biosimilar (搜索) counterparts have the potential to deliver significant savings to both patients and the healthcare system.
Representative Langworthy has been active in proposing healthcare-related legislation, with H.R.9661 joining a portfolio that includes bills addressing healthcare information availability and dietary supplement regulation. Representative Schrier, a physician by training, has similarly advanced multiple health policy initiatives, including the SCREEN for Type 1 Diabetes Act of 2026 and the Strengthening the Vaccines for Children Program Act of 2026.
The bipartisan nature of the bill underscores the shared concern across party lines regarding the affordability of prescription medications and the need to modernize regulatory frameworks to keep pace with scientific advances in biologic development. If enacted, the legislation could reshape the biosimilar (搜索) approval landscape by reducing the time and cost associated with bringing these products to market, potentially accelerating patient access to more affordable treatment options for conditions ranging from autoimmune diseases to cancer.
The bill has been referred to committee for further consideration. Its prospects will depend on the broader legislative calendar and the level of support it can garner from stakeholders across the pharmaceutical industry, patient advocacy groups, and the regulatory community.